AUTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Autolus Therapeutics PLC (AUTL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive analyst ratings and a potential for value creation in the future, the company's financial performance is weak, with declining net income, EPS, and gross margin. Additionally, there are no significant trading signals, news catalysts, or congressional trading data to support a strong buy decision. The stock's technical indicators suggest a neutral to slightly positive trend, but the lack of strong momentum and the company's financial challenges make it prudent to hold off on investing for now.
The MACD histogram is positive and expanding, indicating a bullish momentum. However, the RSI is in the neutral zone, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 1.602, R2: 1.682), which may limit further upside in the short term.
Analysts have a positive outlook on the company's pipeline, particularly the potential of obecabtagene autoleucel to expand into broader markets. The company is also seen as undervalued by some analysts, with a price target as high as $11.
Weak financial performance in the latest quarter, with declining net income, EPS, and gross margin. No recent news, congressional trading data, or significant hedge fund or insider activity to act as a catalyst. Stock trend analysis suggests a potential short-term decline.
In Q3 2025, revenue remained flat year-over-year at $21.19M, while net income dropped by 3.63% to -$79.12M. EPS decreased by 3.23% to -0.3, and gross margin fell significantly to -35.15%. Overall, the financial performance shows no growth and worsening profitability.
Analysts maintain a Buy rating, with price targets ranging from $8 to $11. Analysts highlight the company's pipeline potential and undervaluation but note skepticism about the company's ability to reach breakeven. Breakeven is projected by 2028 based on Aucatzyl sales alone, with additional potential from obe-cel in lupus nephritis.
